CStone Pharmaceuticals (SEHK:2616) Valuation Check After New UK Approval For Sugemalimab In Stage III Lung Cancer

CStone Pharmaceuticals (SEHK:2616) is back on investors radar after the UK regulator granted a new indication for its cancer drug sugemalimab, extending its use in specific stage III lung cancer patients.

See our latest analysis for CStone Pharmaceuticals.

The MHRA decision lands at a time when CStone’s 1 month share price return of 30.91% and 90 day share price return of 18.75% suggest building momentum. However, the 1 year total shareholder return of 100.30% contrasts with a 5 year total shareholder return decline of 22.94%.

If this approval has you looking across the sector, it could be a good moment to widen your watchlist with 120 healthcare AI stocks as potential next candidates to research.

With the wider label for sugemalimab and shares up strongly over the past year, the key question now is simple: is CStone still trading below its estimated worth, or has the market already priced in future growth?

Preferred Price-to-Sales of 42.7x: Is It Justified?

On the numbers provided, CStone looks expensive on a P/S basis, with a 42.7x ratio at a last close of HK$6.65 compared with both peers and the wider Hong Kong biotech space.

The P/S ratio compares the company’s market value with its revenue, and it is often used for businesses that are not yet profitable, like many early and mid stage biopharma names. A higher P/S usually implies the market is willing to pay more today for each unit of current sales.

For CStone, that 42.7x P/S stands well above the peer average of 24x and also above the Hong Kong biotech industry average of 13.4x. It also sits far above the estimated fair P/S of 4.3x that our fair ratio work suggests the market could eventually move toward if expectations change or revenue catches up with the current share price.

Explore the SWS fair ratio for CStone Pharmaceuticals

Result: Price-to-Sales of 42.7x (OVERVALUED)

However, there are still clear risks, including CStone’s reported CN¥377.089m net loss and the possibility that future regulatory or commercial setbacks could cool sentiment.

Find out about the key risks to this CStone Pharmaceuticals narrative.

Another View: DCF Points the Other Way

While the 42.7x P/S ratio hints at a rich price tag, our DCF model lands in a very different place. On that approach, CStone at HK$6.65 is trading around 80.8% below an estimated fair value of HK$34.58, suggesting the market could be heavily discounting its future cash flows.

Look into how the SWS DCF model arrives at its fair value.

With one method calling the shares expensive on sales and the SWS DCF model indicating a large gap to fair value, which lens do you rely on more in your own checklist?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CStone Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 224 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Reading this, you can probably sense that CStone’s story is not one sided, so move quickly, weigh the upside and downside, and check the 2 key rewards and 1 important warning sign before you settle on your own view.

Looking for more investment ideas?

If CStone has sparked your interest, do not stop here. Use the screener to uncover other opportunities that might fit your style before the crowd catches on.

• Target potential mispricings by scanning 224 high quality undervalued stocks that pair solid fundamentals with price tags that may not fully reflect their strengths.
• Build a steadier income stream by reviewing 461 dividend fortresses that focus on higher yielding companies with the potential to support regular payouts.
• Strengthen your core holdings by checking solid balance sheet and fundamentals stocks screener (373 results) that prioritise companies with cleaner debt profiles and more resilient finances.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com